Rewiring the Engine: How Metabolism Could Unlock CAR-T Cells for Solid Tumors

Chimeric antigen receptor T cell therapy has delivered some of the most striking results in modern oncology, producing durable remissions in patients with blood cancers whose disease had resisted every conventional option. Yet the same technology has repeatedly stumbled when aimed at solid tumors, and a new review published in the Journal of Translational Medicine argues that the explanation lies not in the genetic engineering of the receptor itself, but in the cellular power plants that keep engineered immune cells alive and fighting. The review, led by Yinglu Liu, Jingchao Su, Zhuojin Song and Shiyi Liu of Southern Medical University together with colleagues, synthesizes a decade of evidence pointing to a single conclusion: metabolic fitness is the primary arbiter of whether a CAR-T cell thrives, fades quietly into memory, or collapses into terminal exhaustion.

The central argument of the paper rests on the observation that T cells do not simply burn fuel at a constant rate. Instead, their metabolism undergoes dramatic, tightly choreographed shifts as they move through their life cycle. Naive T cells idle along on oxidative phosphorylation, a slow but efficient mode of energy production that relies on mitochondria and a steady supply of nutrients. When a T cell recognizes its target, it pivots sharply toward aerobic glycolysis, the Warburg-like program in which glucose is consumed voraciously and fermented into lactate even in the presence of oxygen. This switch, governed by master regulators such as hypoxia-inducible factor 1-alpha and the nutrient-sensing kinase complex mTORC1, supplies the biosynthetic building blocks a dividing cell needs to clonal-expand and deploy its cytotoxic arsenal. When the threat clears, surviving cells contract again, this time favoring fatty acid oxidation and mitochondrial spare respiratory capacity, the metabolic signature of long-lived memory cells that can respond rapidly to future encounters.

CAR-T cells, the authors emphasize, are forced through all of these transitions within a matter of days, and the way they navigate them determines their clinical fate. Cells that adopt a balanced program, blending glycolytic burst with robust mitochondrial reserve, persist in the patient and maintain antitumor activity for months or years. Cells that overshoot, burning through their resources in a hyperactive glycolytic sprint, are far more likely to terminally differentiate and exhaust, losing cytotoxic function and acquiring a transcriptional profile dominated by inhibitory receptors. The review frames this as a continuum orchestrated by metabolic state, with quiescence, effector activation and exhaustion representing divergent outcomes of the same underlying bioenergetic decisions.

The problem becomes acute inside solid tumors, where CAR-T cells must operate in one of the most metabolically hostile environments in the human body. The tumor microenvironment is characterized by severe glucose deprivation, because the tumor cells themselves consume glucose at a ferocious rate. It is hypoxic, with oxygen tensions far below those needed for efficient mitochondrial respiration. It is acidic and laden with toxic metabolites, including lactate secreted by tumor cells, adenosine generated by the ectonucleotidases CD39 and CD73, and catabolized amino acids such as arginine and tryptophan, the latter degraded by indoleamine 2,3-dioxygenase 1 expressed by tumor and stromal cells. Each of these factors independently impairs T cell function; together, they create a metabolic gauntlet that exhausts even the most potent engineered cells.

The review details how tumor-associated macrophages, myeloid-derived suppressor cells, cancer-associated fibroblasts and regulatory T cells compound this hostility by competing for nutrients and actively secreting immunosuppressive metabolites. Arginase 1 produced by myeloid suppressor cells depletes extracellular arginine, which T cells require for proliferation and for the maintenance of mitochondrial function. Adenosine acting through the A2A receptor on T cells elevates intracellular cyclic AMP and suppresses effector cytokine production. Lactate imported through monocarboxylate transporters acidifies the T cell cytoplasm and impairs glycolytic flux. In effect, the tumor does not merely hide from immune attack; it weaponizes the chemistry of its own waste products.

Against this backdrop, the authors survey a rapidly expanding toolkit of metabolic engineering strategies designed to harden CAR-T cells against these pressures. Genetic approaches include overexpression of glucose transporters GLUT1 and GLUT3 to improve glucose scavenging, enforced expression of the mitochondrial pyruvate carrier or carnitine palmitoyltransferase 1A to boost oxidative metabolism and fatty acid oxidation, and deletion of negative regulators such as diacylglycerol kinase or the stress kinase PDK1 to sustain mitochondrial respiration. Transcriptional regulators have emerged as particularly powerful levers: the forkhead transcription factor FOXO1 and the coactivator PGC-1α promote mitochondrial biogenesis and memory-like differentiation, while knocking down NR4A family factors or BATF can prevent the exhaustion program from taking hold. Interleukin-driven signaling through mTOR and AMP-activated protein kinase can be tuned pharmacologically as well, with mTOR inhibitors such as rapamycin used during manufacturing to bias cells toward a central-memory phenotype with superior persistence.

The review also highlights less obvious metabolic vulnerabilities, including ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation that has been implicated in CAR-T cell demise within tumors. Reinforcing the antioxidant defenses of engineered cells, for example through glutathione peroxidase 4 or systems that maintain reduced glutathione pools, may allow CAR-T cells to survive the oxidative stress of the tumor microenvironment. Amino acid metabolism offers another frontier: enhancing uptake of cationic amino acids through transporters such as SLC7A5, or engineering resistance to tryptophan starvation by modulating the GCN2 stress-response pathway and the transcription factor ATF4, could keep cells functional where nutrients are scarce. Even epigenetic metabolism enters the picture, since the methyl donor S-adenosylmethionine and the tricarboxylic acid cycle intermediate α-ketoglutarate influence chromatin states that determine whether exhaustion-related genes remain silenced.

Crucially, the authors argue that intrinsic rewiring of the cells alone will not suffice, and they advocate a unified model in which CAR-T engineering is synchronized with extrinsic modulation of the tumor microenvironment. Candidate strategies include depleting suppressive metabolites with inhibitors of IDO1 or adenosine-signaling pathways, reprogramming tumor-associated macrophages and fibroblasts, and deploying CAR-T cells whose receptors are wired to hypoxia response elements so that therapeutic payload expression is confined to the tumor. The microbiota also emerges as an unexpected variable, with short-chain fatty acids and other microbial metabolites capable of shaping systemic T cell metabolism and potentially influencing the success or failure of adoptive cell therapy.

The path to the clinic, the review cautions, is not straightforward. Many metabolic manipulations that enhance persistence in mouse models have uncertain effects in humans, and some, such as broad mTOR inhibition, carry risks of blunting the very cytotoxicity that makes CAR-T cells effective. Manufacturing under good manufacturing practice conditions adds further constraints, since every genetic modification must be compatible with scalable, reproducible production. Safety considerations extend to the well-known toxicities of CAR-T therapy, cytokine release syndrome and immune effector cell-associated neurotoxicity, both of which are themselves influenced by the metabolic state of the infused cells. The authors close with a vision in which metabolic profiling of each patient’s tumor microenvironment guides a customized combination of intrinsic cell engineering and extrinsic pathway modulation, transforming CAR-T therapy from a one-size-fits-all product into a metabolically tailored intervention. If that vision is realized, the barriers that have confined this revolutionary therapy to liquid cancers may finally begin to fall.

Subject of Research: Metabolic reprogramming strategies to improve CAR-T cell therapy, particularly against solid tumors

Article Title: Metabolic reprogramming for CAR-T cell therapy: advances and perspectives

Article References: Liu, Y., Su, J., Song, Z., Liu, S., Huang, M., Zeng, Y., Ou, K., Wu, Y., Chen, M., Li, Y., & Tu, S. (2026). Metabolic reprogramming for CAR-T cell therapy: advances and perspectives. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08982-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08982-6

Keywords: CAR-T cell therapy, metabolic reprogramming, tumor microenvironment, T cell exhaustion, glycolysis, mitochondrial fitness, ferroptosis, hypoxia, gene editing, immunometabolism, solid tumors, clinical translation